Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN-COVID: Canakinumab for cytokine release syndrome in COVID-19 pneumonia
2020-001370-30Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus pneumonia, coronavirus disease 2019 (COVID-19) and cytokine release syndrome (CRS) comparing Canakinumab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Clinical response (primary). Started Apr 2020; status: completed.
02
Drugs
canakinumab
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on 2020-001370-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001370-30.